What is Trodelvy? | Information & FAQ | TheSocialMedwork



Article reviewed by Dr. Jan de Witt

Article last updated on 22/1/2021


What is Trodelvy (sacituzumab govitecan-hziy)?

Trodelvy is an antibody-drug conjugate (ADC; an immune targeted therapy). It is used for the treatment of patients with metastatic triple-negative breast cancer (mTNBC), who have received at least 2 previous therapies for metastatic disease. Trodelvy is the first ADC the FDA has approved for the treatment of people with mTNBBC.1


How much does Trodelvy (sacituzumab govitecan-hziy) cost?

For more information about how much Trodelvy costs and how we can help you access it, please click on the button below:


What is Trodelvy (sacituzumab govitecan-hziy) used for?

Trodelvy is a medication used for the treatment of patients with metastatic triple-negative breast cancer (mTNBC), who have received at least 2 previous therapies for metastatic disease. TNBC accounts for up to 20% of all breast cancers.1

Trodelvy is currently also under investigation for the treatment of patients with bladder cancer or glioblastoma, an aggressive type of brain cancer.2,3


Is Trodelvy (sacituzumab govitecan-hziy) a chemotherapy?

Trodelvy is an immune targeted therapy medicine which consists of a monoclonal antibody (sacituzumab) that can help the immune system recognize and fight the cancer. Trodelvy is a so-called antibody-drug conjugate (ADC): a linking compound attaches (conjugates) sacituzumab to the SN-38 chemotherapy.1,4


What is Sacituzumab Govitecan HZIY?

Sacituzumab Govitecan is a Trop-2-directed antibody-drug conjugate (ADC). Sacituzumab Govitecan is made up of 3 parts:4

  • Sacituzumab, a Trop-2-recognizing antibody, which is a type of protein designed to recognise and attach to the Trop2 antigen present on cancer cells.
  • SN-38, a topoisomerase I inhibitor (chemotherapy), which damages the tumor cell’s DNA and inhibits further DNA replication.
  • A compound that conjugates (links) these two parts together.

How does Trodelvy (sacituzumab govitecan-hziy) work?

When sacituzumab binds to Trop-2 on the cancer cell, the drug is taken up by the cell and the linker is broken. This causes the release of SN-38, which will then destroy the Trop-2-positive cancer cells.1,4


Who makes Trodelvy sacituzumab govitecan-hziy)?

Trodelvy is made by Immunomedics. Immunomedics is specialised in next-generation antibody-drug conjugate (ADC) technology, and they aim to help patients with hard-to-treat cancers. Trodelvy is the company's lead ADC.


What happened to Immunomedics?

On September 13, 2020, Gilead and Immunomedics announced that they had signed a definitive merger agreement. Immunomedics has become a wholly owned subsidiary of Gilead. Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need.5


References

  1. Access.fda.gov
  2. Immunomedics.com
  3. Biospace.com
  4. Trodelvy - Breastcancer.org
  5. Gilead.com
  6. Trodelvy (sacituzumab govitecan-hziy) - Thesocialmedwork.com

Contact Patient Support

If you have any questions or need any help, contact our Patient Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 18:00 CET.